Dimensional Fund Advisors LP Boosts Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Dimensional Fund Advisors LP grew its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 24.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 700,212 shares of the medical device company's stock after purchasing an additional 136,015 shares during the period. Dimensional Fund Advisors LP owned about 1.44% of AtriCure worth $21,398,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the stock. Kennedy Capital Management LLC increased its holdings in AtriCure by 29.8% during the fourth quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company's stock valued at $22,999,000 after buying an additional 172,648 shares during the period. Marshall Wace LLP increased its holdings in shares of AtriCure by 37.1% in the 4th quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company's stock valued at $18,922,000 after acquiring an additional 167,476 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of AtriCure by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 399,428 shares of the medical device company's stock worth $12,207,000 after acquiring an additional 4,844 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in shares of AtriCure by 43.1% during the 4th quarter. JPMorgan Chase & Co. now owns 365,183 shares of the medical device company's stock worth $11,160,000 after purchasing an additional 110,039 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its position in AtriCure by 2.7% during the fourth quarter. Bank of New York Mellon Corp now owns 258,272 shares of the medical device company's stock valued at $7,893,000 after purchasing an additional 6,809 shares in the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

AtriCure Stock Performance

Shares of NASDAQ:ATRC traded down $0.19 during midday trading on Friday, reaching $30.99. The company's stock had a trading volume of 625,247 shares, compared to its average volume of 656,420. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. The stock has a fifty day moving average of $32.71 and a 200 day moving average of $34.78. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11. The firm has a market capitalization of $1.53 billion, a PE ratio of -32.62 and a beta of 1.57.

AtriCure (NASDAQ:ATRC - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.11. AtriCure had a negative return on equity of 6.80% and a negative net margin of 9.61%. The business had revenue of $123.62 million during the quarter, compared to analyst estimates of $122.92 million. During the same quarter last year, the business posted ($0.28) EPS. The company's revenue was up 13.5% on a year-over-year basis. On average, equities analysts expect that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

Insider Transactions at AtriCure

In related news, Director Karen Prange sold 6,100 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the sale, the director now directly owns 17,828 shares of the company's stock, valued at approximately $679,603.36. This represents a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 3.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ATRC. Stifel Nicolaus raised their price target on shares of AtriCure from $36.00 to $48.00 and gave the company a "buy" rating in a report on Thursday, February 13th. Piper Sandler lifted their price target on shares of AtriCure from $40.00 to $50.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Oppenheimer increased their price objective on AtriCure from $36.00 to $45.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Needham & Company LLC reduced their target price on AtriCure from $51.00 to $44.00 and set a "buy" rating on the stock in a research report on Wednesday, April 30th. Finally, Canaccord Genuity Group lowered their price target on AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a report on Friday, March 28th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, AtriCure currently has an average rating of "Moderate Buy" and an average price target of $50.67.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.